Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia

Franklin O. Smith, Roberta King, Gene Nelson, Kent Robertson, Kent A. Robertson, Jean E. Sanders, Nancy Bunin, Peter D. Emaunel, Stella M. Davies

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Children with juvenile myelomonocytic leukaemia (JMML) have a poor outcome, with survival in a minority of patients. The major limitation on success of sibling donor bone marrow transplantation for JMML has been reported to be relapse. A total of 46 children with a diagnosis of JMML underwent unrelated donor marrow (URD) transplantation facilitated by the National Marrow Donor Program. Forty-three of 46 patients had neutrophil engraftment at a median of 20 d post transplant, with platelet recovery in 28 of 40 evaluable patients at a median of 34.5 d. Thirty-two of 44 evaluable patients developed acute graft-versus-host-disease (GVHD) (Grades 2-4) and chronic GVHD developed in 14 of 35 evaluable patients. At a median follow-up of 2.0 years, probabilities of survival and disease-free survival were 42% and 24% respectively. The probability of relapse was 58% at 2 years and represents the major cause of treatment failure. Multivariate analysis revealed that chronic GVHD was associated with reduced relapse [risk ratio 0.20 (95% CI 0.04-1.02, P = 0.05)] improved survival [risk ratio 0.13 (95% CI 0.03-0.68, P = 0.02)] and event-free survival [risk ratio 0.23 (95% CI 0.06-0.94, P = 0.04)]. This study demonstrates that relapse is the major cause of treatment failure in patients with JMML undergoing URD transplantation. With lower relapse observed in patients with chronic GVHD, new treatment strategies that focus on enhancing the graft-versus-leukaemia effect may improve survival.

Original languageEnglish (US)
Pages (from-to)716-724
Number of pages9
JournalBritish Journal of Haematology
Volume116
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Juvenile Myelomonocytic Leukemia
Unrelated Donors
Bone Marrow Transplantation
Graft vs Host Disease
Recurrence
Survival
Bone Marrow
Odds Ratio
Treatment Failure
Disease-Free Survival
Transplantation
Tissue Donors
Transplants
Siblings
Leukemia
Neutrophils
Blood Platelets
Multivariate Analysis

Keywords

  • Bone marrow transplantation
  • Graft-versus-host disease
  • Juvenile myelomonocytic leukaemia
  • National Marrow Donor Program
  • Relapse

ASJC Scopus subject areas

  • Hematology

Cite this

Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. / Smith, Franklin O.; King, Roberta; Nelson, Gene; Robertson, Kent; Robertson, Kent A.; Sanders, Jean E.; Bunin, Nancy; Emaunel, Peter D.; Davies, Stella M.

In: British Journal of Haematology, Vol. 116, No. 3, 2002, p. 716-724.

Research output: Contribution to journalArticle

Smith, FO, King, R, Nelson, G, Robertson, K, Robertson, KA, Sanders, JE, Bunin, N, Emaunel, PD & Davies, SM 2002, 'Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia', British Journal of Haematology, vol. 116, no. 3, pp. 716-724. https://doi.org/10.1046/j.0007-1048.2001.03333.x
Smith, Franklin O. ; King, Roberta ; Nelson, Gene ; Robertson, Kent ; Robertson, Kent A. ; Sanders, Jean E. ; Bunin, Nancy ; Emaunel, Peter D. ; Davies, Stella M. / Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. In: British Journal of Haematology. 2002 ; Vol. 116, No. 3. pp. 716-724.
@article{b5f5d2e591204f08b63fefa3db72465d,
title = "Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia",
abstract = "Children with juvenile myelomonocytic leukaemia (JMML) have a poor outcome, with survival in a minority of patients. The major limitation on success of sibling donor bone marrow transplantation for JMML has been reported to be relapse. A total of 46 children with a diagnosis of JMML underwent unrelated donor marrow (URD) transplantation facilitated by the National Marrow Donor Program. Forty-three of 46 patients had neutrophil engraftment at a median of 20 d post transplant, with platelet recovery in 28 of 40 evaluable patients at a median of 34.5 d. Thirty-two of 44 evaluable patients developed acute graft-versus-host-disease (GVHD) (Grades 2-4) and chronic GVHD developed in 14 of 35 evaluable patients. At a median follow-up of 2.0 years, probabilities of survival and disease-free survival were 42{\%} and 24{\%} respectively. The probability of relapse was 58{\%} at 2 years and represents the major cause of treatment failure. Multivariate analysis revealed that chronic GVHD was associated with reduced relapse [risk ratio 0.20 (95{\%} CI 0.04-1.02, P = 0.05)] improved survival [risk ratio 0.13 (95{\%} CI 0.03-0.68, P = 0.02)] and event-free survival [risk ratio 0.23 (95{\%} CI 0.06-0.94, P = 0.04)]. This study demonstrates that relapse is the major cause of treatment failure in patients with JMML undergoing URD transplantation. With lower relapse observed in patients with chronic GVHD, new treatment strategies that focus on enhancing the graft-versus-leukaemia effect may improve survival.",
keywords = "Bone marrow transplantation, Graft-versus-host disease, Juvenile myelomonocytic leukaemia, National Marrow Donor Program, Relapse",
author = "Smith, {Franklin O.} and Roberta King and Gene Nelson and Kent Robertson and Robertson, {Kent A.} and Sanders, {Jean E.} and Nancy Bunin and Emaunel, {Peter D.} and Davies, {Stella M.}",
year = "2002",
doi = "10.1046/j.0007-1048.2001.03333.x",
language = "English (US)",
volume = "116",
pages = "716--724",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia

AU - Smith, Franklin O.

AU - King, Roberta

AU - Nelson, Gene

AU - Robertson, Kent

AU - Robertson, Kent A.

AU - Sanders, Jean E.

AU - Bunin, Nancy

AU - Emaunel, Peter D.

AU - Davies, Stella M.

PY - 2002

Y1 - 2002

N2 - Children with juvenile myelomonocytic leukaemia (JMML) have a poor outcome, with survival in a minority of patients. The major limitation on success of sibling donor bone marrow transplantation for JMML has been reported to be relapse. A total of 46 children with a diagnosis of JMML underwent unrelated donor marrow (URD) transplantation facilitated by the National Marrow Donor Program. Forty-three of 46 patients had neutrophil engraftment at a median of 20 d post transplant, with platelet recovery in 28 of 40 evaluable patients at a median of 34.5 d. Thirty-two of 44 evaluable patients developed acute graft-versus-host-disease (GVHD) (Grades 2-4) and chronic GVHD developed in 14 of 35 evaluable patients. At a median follow-up of 2.0 years, probabilities of survival and disease-free survival were 42% and 24% respectively. The probability of relapse was 58% at 2 years and represents the major cause of treatment failure. Multivariate analysis revealed that chronic GVHD was associated with reduced relapse [risk ratio 0.20 (95% CI 0.04-1.02, P = 0.05)] improved survival [risk ratio 0.13 (95% CI 0.03-0.68, P = 0.02)] and event-free survival [risk ratio 0.23 (95% CI 0.06-0.94, P = 0.04)]. This study demonstrates that relapse is the major cause of treatment failure in patients with JMML undergoing URD transplantation. With lower relapse observed in patients with chronic GVHD, new treatment strategies that focus on enhancing the graft-versus-leukaemia effect may improve survival.

AB - Children with juvenile myelomonocytic leukaemia (JMML) have a poor outcome, with survival in a minority of patients. The major limitation on success of sibling donor bone marrow transplantation for JMML has been reported to be relapse. A total of 46 children with a diagnosis of JMML underwent unrelated donor marrow (URD) transplantation facilitated by the National Marrow Donor Program. Forty-three of 46 patients had neutrophil engraftment at a median of 20 d post transplant, with platelet recovery in 28 of 40 evaluable patients at a median of 34.5 d. Thirty-two of 44 evaluable patients developed acute graft-versus-host-disease (GVHD) (Grades 2-4) and chronic GVHD developed in 14 of 35 evaluable patients. At a median follow-up of 2.0 years, probabilities of survival and disease-free survival were 42% and 24% respectively. The probability of relapse was 58% at 2 years and represents the major cause of treatment failure. Multivariate analysis revealed that chronic GVHD was associated with reduced relapse [risk ratio 0.20 (95% CI 0.04-1.02, P = 0.05)] improved survival [risk ratio 0.13 (95% CI 0.03-0.68, P = 0.02)] and event-free survival [risk ratio 0.23 (95% CI 0.06-0.94, P = 0.04)]. This study demonstrates that relapse is the major cause of treatment failure in patients with JMML undergoing URD transplantation. With lower relapse observed in patients with chronic GVHD, new treatment strategies that focus on enhancing the graft-versus-leukaemia effect may improve survival.

KW - Bone marrow transplantation

KW - Graft-versus-host disease

KW - Juvenile myelomonocytic leukaemia

KW - National Marrow Donor Program

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=0036183285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036183285&partnerID=8YFLogxK

U2 - 10.1046/j.0007-1048.2001.03333.x

DO - 10.1046/j.0007-1048.2001.03333.x

M3 - Article

VL - 116

SP - 716

EP - 724

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -